Causative factors for prolonged hospitalization beyond the point of engraftment in patients after autologous peripheral blood stem cell transplantation
- 1 October 2000
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 26 (8) , 877-880
- https://doi.org/10.1038/sj.bmt.1702632
Abstract
In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. One hundred patients (receiving 123 conditioning regimens) were included in the analysis. Criteria for discharge were presence of myeloid engraftment and absence of severe concomitant problems. Ninety subjects (73%) were discharged just after engraftment was reached on day +12 (10-14). Discharge was delayed in 33 patients (27%) and the mean prolongation was 3 days (1-11). In 31 patients (25%) delayed discharge was due to complications: in 14 patients (11.4%) because of GIT problems, in 16 patients (13%) because of infectious complications and in one patient because of cardiotoxicity. A significantly higher number of infectious complications was found in patients conditioned with BEAM (19.7% vs 4.2%, P < 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m2 (8.2% vs 14.7%, NS). No risk factors of hospital stay prolongation were determined. We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT.Keywords
This publication has 13 references indexed in Scilit:
- Costs of intensive treatment and follow-up of patients with multiple myelomaAnti-Cancer Drugs, 1998
- The economic evaluation of hematopoietic growth factors in high-dose chemotherapyAnti-Cancer Drugs, 1998
- Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cellsBone Marrow Transplantation, 1998
- Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trialBone Marrow Transplantation, 1998
- Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantationBone Marrow Transplantation, 1997
- Peripheral stem cell mobilization and engraftment in patients over age 60Bone Marrow Transplantation, 1997
- Cyclophosphamide 3 g/m2and G-CSF is an effective and safe outpatient-based PBSC mobilising regimen: a single centre experienceBone Marrow Transplantation, 1997
- Colony-Stimulating Factors and Peripheral Blood Progenitor Cell TransplantationPharmacoEconomics, 1996
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerNew England Journal of Medicine, 1991
- Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapyBlood, 1988